Loading...
Safety of grass pollen sublingual immunotherapy for allergic rhinitis in concomitant asthma
Sahadevan, A Cusack, R Lane, SJ
Sahadevan, A
Cusack, R
Lane, SJ
Authors
Advisors
Editors
Other Contributors
Departments
Date
2015-12
Date Submitted
Keywords
RHINITIS
HAY FEVER
ASTHMA
HAY FEVER
ASTHMA
Other Subjects
Subject Mesh
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
Main Article
Adobe PDF, 23.38 KB
Alternative Titles
Publisher
Abstract
Seasonal allergic rhinitis (AR) occurs predominantly as a result of grass pollen allergy. Grass pollen sublingual immunotherapy (SLIT) has been proven effective in treating AR 1 . SLIT is currently licensed for use in AR with concomitant stable mild asthma. There is evidence that SLIT improves asthma control when primarily used to treat AR 2 . The aim was to assess the safety of SLIT in patients with severe seasonal allergic rhinitis who have co-existing stable mild asthma. The secondary aim was to determine whether asthma control improved post SLIT. There was no deterioration in asthma control after 6-36 months of SLIT. 27/30 (90%) patientsâ asthma control remained stable or indeed improved (p<0.021). Of this 15 (50%) patientsâ asthma improved. There was no statistically significant change in their asthma pharmacotherapy after SLIT (p=0.059). In conclusion, grass pollen SLIT is safe and can potentially treat dual allergic rhinitis- mild asthmatic patients.
Language
en